Creating new imaging agents to improve surgery for hyperparathyroidism
The development of novel PET/NIRF agents for hyperparathyroidism management
This study is testing new imaging tools to help doctors find tricky-to-locate parathyroid glands in patients with primary hyperparathyroidism, making surgeries safer and more effective for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10911916 on NIH RePORTER |
What this research studies
This research focuses on developing innovative imaging agents that can help locate abnormal parathyroid glands in patients with primary hyperparathyroidism (PHPT). By using advanced techniques like positron emission tomography (PET) and near-infrared fluorescence (NIRF), the study aims to enhance the accuracy of preoperative imaging and guide surgeons during operations. This could lead to more effective surgeries with fewer complications, as the new agents are designed to detect small or unusually located glands that current methods struggle to identify. Patients may benefit from a more targeted surgical approach, reducing unnecessary procedures and improving outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with primary hyperparathyroidism who are considering surgical intervention.
Not a fit: Patients who do not have hyperparathyroidism or those who are not surgical candidates may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise surgeries for patients with hyperparathyroidism, minimizing complications and improving recovery times.
How similar studies have performed: Previous research has shown promise in developing imaging agents for similar applications, indicating potential for success in this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Wu, Zhanhong — Univ of North Carolina Chapel Hill
- Study coordinator: Wu, Zhanhong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.